Clinical Trial Update: Botulinum Toxin Type A for Injection (HengLi®) in the Treatment of Trigeminal Neuralgia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of HengLi®, a Botulinum Toxin Type A injection, for trigeminal neuralgia, is currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Trigeminal Neuralgia

Drugs mentioned

• HengLi® (Botulinum toxin type A)

Snippet

Sponsor: LKGS_277 | Conditions: Trigeminal Neuralgia | Phase 2 | Status: ENROLLING_BY_INVITATION